Status:
COMPLETED
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months
- HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)
- FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L
- BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)
Exclusion
- Metformin contraindications according to local practice
- Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT00627445
Start Date
February 1 2008
End Date
January 1 2009
Last Update
October 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, Beijing Municipality, China, 100034